After the All-Clear: What Integrative Cancer Support Looks Like Now

By Your Health Magazine Contributor

Your Health Magazine Contributor

. https://YourHealthMagazine.net

More Cancer Awareness Articles

After the All-Clear: What Integrative Cancer Support Looks Like Now

Every October, Breast Cancer Awareness Month puts screening and early detection front and center, and for good reason. What gets far less attention is the stretch that comes after. Treatment ends, the scans look good, and patients are told they are in remission. For many people, that is where the plan stops. For a growing number of patients, it is where a second set of questions starts.

Remission is not always the end of the story

A clear scan is real good news. It also has limits. Imaging is designed to identify detectable tumors and other changes, while circulating tumor cells are individual cancer cells that can sometimes be found in the bloodstream. Researchers continue to study whether detecting these cells can provide useful information about recurrence risk in certain cancers.

Circulating tumor cell testing is not a standard surveillance tool for every cancer survivor, and results should be interpreted alongside conventional oncology follow-up rather than in place of it. Some integrative cancer support programs offer this type of testing as an additional source of information.

What RGCC testing looks for

One of the tools integrative clinics use is RGCC testing, a specialized blood test developed in Greece and now offered by providers across the United States. From a standard blood draw, the lab looks for circulating tumor cells and analyzes their characteristics.

RGCC reports can include information about circulating tumor cells and how collected cells respond in the laboratory to a range of substances. However, laboratory sensitivity results do not necessarily predict how a treatment will work in a patient, and this type of testing should not replace established oncology testing, surveillance or treatment recommendations. Results can be discussed with the patient’s oncology team when considering how they fit into the broader clinical picture.

High-dose vitamin C and ozone therapy

Two therapies come up often in integrative cancer care, and both are delivered intravenously or through the blood.

High-dose IV vitamin C. Vitamin C taken by mouth is limited by how much the gut can absorb. Given through an IV, it can reach blood levels that oral supplements cannot. At those levels, vitamin C acts differently than it does in a daily multivitamin. High-dose IV vitamin C has been studied alongside conventional cancer treatment, including for possible effects on quality of life and treatment-related side effects, but research results remain mixed and it is not FDA-approved as a cancer treatment. Evidence that it reduces circulating tumor cells or improves cancer outcomes has not been established.

Ozone therapy. Some integrative providers offer forms of ozone therapy in which blood is removed, exposed to a controlled ozone-oxygen mixture and returned to the body. Ozone therapy has been studied for several medical uses, including supportive-care applications, but evidence for its use as part of cancer care remains limited and it has not been established as a treatment for cancer. Patients considering it should discuss the potential risks, uncertain benefits and possible interactions with their oncology team.

Neither therapy is a cure, and neither is a substitute for chemotherapy, radiation or surgery. They are tools that a medical team chooses for a specific patient based on testing, history and goals.

What a good integrative program includes

If you or someone you love is exploring integrative cancer support, these are signs of a program worth trusting:

• Testing comes first. A plan should be built from lab work, including baseline screening that confirms a high-dose infusion is safe for you.
• Medical supervision. Infusions should be prescribed and overseen by licensed providers, with nurses trained in high-dose protocols.
• A plan that changes over time. Follow-up testing should shape what happens next, rather than repeating the same infusion indefinitely.
• Straight answers. Providers should explain what a therapy is designed to support and what it is not.

A local example in Oklahoma

Patients in the Tulsa area have access to this kind of care close to home. WellSpot IV, a medically supervised IV therapy clinic in Owasso, Oklahoma, offers an integrative cancer support program that includes RGCC testing, high-dose IV vitamin C and ozone therapy, with each plan built by its medical team around a patient’s lab results. Patients who want to understand how the program works can find details at wellspotiv.com.

Awareness that lasts past October

Breast Cancer Awareness Month is a good time to schedule a screening and to talk with the women in your life about theirs. It is also a good time to remember that survivorship is its own phase of care. Asking what comes after the all-clear, and what testing and support are available, is a reasonable question for any patient to bring to their care team.